These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 36253762)

  • 1. Tumor microenvironment: barrier or opportunity towards effective cancer therapy.
    Tiwari A; Trivedi R; Lin SY
    J Biomed Sci; 2022 Oct; 29(1):83. PubMed ID: 36253762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Omics Profiling of the Tumor Microenvironment.
    Van Oekelen O; Laganà A
    Adv Exp Med Biol; 2022; 1361():283-326. PubMed ID: 35230695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor microenvironment: shaping cancer progression and treatment response.
    Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
    J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
    Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
    Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
    Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
    Cells; 2022 May; 11(9):. PubMed ID: 35563889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment as a complex milieu driving cancer progression: a mini review.
    Li Z; Li J; Bai X; Huang X; Wang Q
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39342061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.
    Bagaev A; Kotlov N; Nomie K; Svekolkin V; Gafurov A; Isaeva O; Osokin N; Kozlov I; Frenkel F; Gancharova O; Almog N; Tsiper M; Ataullakhanov R; Fowler N
    Cancer Cell; 2021 Jun; 39(6):845-865.e7. PubMed ID: 34019806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
    Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
    Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
    Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
    Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
    Jenkins S; Wesolowski R; Gatti-Mays ME
    Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
    Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
    Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
    Anari F; Ramamurthy C; Zibelman M
    Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies.
    Peng X; Zheng J; Liu T; Zhou Z; Song C; Geng Y; Wang Z; Huang Y
    Curr Cancer Drug Targets; 2024; 24(3):288-307. PubMed ID: 37537777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
    Oliver AJ; Lau PKH; Unsworth AS; Loi S; Darcy PK; Kershaw MH; Slaney CY
    Front Immunol; 2018; 9():70. PubMed ID: 29445373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
    Jiang T; Chen X; Ren X; Yang JM; Cheng Y
    Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning.
    Ye Z; Zeng D; Zhou R; Shi M; Liao W
    Front Immunol; 2022; 13():819807. PubMed ID: 35603201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.